Adenosine deaminase缺乏型重症合併免疫力缺乏（ADA-SCID）市場規模、佔有率和成長分析：按治療類型、治療階段、給藥途徑、最終用戶、分銷管道和地區分類－2026-2033年行業預測

2024 年，Adenosine deaminase缺乏型重症聯合免疫力缺乏(ADA-SCID) 的全球市場規模為 2.841 億美元，預計將從 2025 年的 3.0063 億美元成長到 2033 年的 796 萬美元，在預測期（2026-2033 年）成長到 2033 年的複合年成長率。

全球Adenosine deaminase缺乏型重症合併免疫力缺乏(ADA-SCID) 市場由創新療法驅動，這些療法旨在補充或糾正缺乏的酶，而這種酶對於預防脆弱嬰兒發生危及生命的感染疾病至關重要。由於該疾病罕見且治療費用高昂，各國政府和保險公司正日益加強對先進療法的支持。這個市場的發展特點是酵素替代療法和突破性基因編輯技術（包括 CRISPR）的出現。這些技術能夠以更少的治療次數達到持續的免疫重建。隨著開發平臺的擴展，基因編輯的自動化提高了生產效率，降低了成本，並使小規模的生物技術公司得以進入市場。在真實世界數據的支持下，這一趨勢正在吸引投資者，擴大全球患者的治療機會，並最終推動市場成長。

全球Adenosine deaminase缺乏型重症合併免疫力缺乏（ADA-SCID）市場成長要素

Adenosine deaminase缺乏症重症合併免疫力缺乏（ADA-SCID）市場的成長主要得益於基因治療技術的進步，這些進步帶來了更高的安全性、更有效率的生產流程以及更廣泛的法規核准。這些因素降低了臨床醫生和患者的就醫門檻，從而增強了醫療專業人員的信心，並鼓勵對專業設施的投資。這一趨勢正在加速臨床試驗的患者招募，最終擴大市場覆蓋範圍，並促進各地區的穩定成長。此外，它還建構了一個支持性生態系統，促進學術機構、生技公司和患者權益組織之間的合作，從而增強了整體市場的發展勢頭。

全球Adenosine deaminase缺乏型重症合併免疫力缺乏（ADA-SCID）市場的限制因素

全球Adenosine deaminase缺乏型重症合併免疫力缺乏症（ADA-SCID）市場面臨許多挑戰，主要源自於基因治療的複雜性。生產流程、特殊的給藥系統以及嚴密的臨床監測需求導致成本高昂，使得醫保報銷困難重重。支付方通常要求進行詳細的成本效益評估，這可能導致報銷決定延遲或受限，從而限制患者獲得治療的機會，並阻礙醫療專業人員採用相關療法。這些財務挑戰構成障礙，減少了潛在接受治療的患者數量，並減緩了對必要輔助服務的投資。此外，資助計畫的限制往往也限制了臨床試驗的參與，進一步阻礙了市場發展。

Adenosine deaminase缺乏症重症合併免疫力缺乏（ADA-SCID）的全球市場趨勢

Adenosine deaminase缺乏免疫力缺乏（ADA-SCID）的全球市場正經歷一場變革，而創新基因療法正是推動這項變革的動力。包括CRISPR-Cas9和鹼基編輯在內的前沿基因編輯技術，正在革新Adenosine deaminase缺乏症的治療方法，以前所未有的精準度糾正致病突變，同時保持免疫系統的完整性。在合作研究舉措的推動下，這一系列進展在臨床前和早期臨床試驗中取得了令人鼓舞的成果，並展現出良好的安全性。生技公司不斷增加的投資正在拓展創新療法的研發管線，這預示著在傳統酵素替代療法之外，兒童及其家庭的長期疾病管理將取得重大進展。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球Adenosine deaminase缺乏型重症合併免疫力缺乏(ADA-SCID) 市場規模：依治療類型分類

• 酵素替代療法（ERT）
• 造血幹細胞移植（HSCT）
• 基因治療

全球Adenosine deaminase缺乏型重症合併免疫力缺乏(ADA-SCID) 市場規模：依治療階段分類

• 首次治療
• 後續治療/挽救治療

全球Adenosine deaminase缺乏型重症合併免疫力缺乏（ADA-SCID）市場規模：依給藥途徑分類

• 靜脈注射（IV）
• 肌肉內注射（IM）

全球Adenosine deaminase缺乏型重症合併免疫力缺乏（ADA-SCID）市場規模：依最終用戶分類

• 醫院
• 專科診所
• 移植中心

全球Adenosine deaminase缺乏型重症聯合免疫力缺乏(ADA-SCID) 市場規模：依分銷管道分類

• 醫院藥房
• 專科藥房

全球Adenosine deaminase缺乏型重症合併免疫力缺乏(ADA-SCID) 市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Leadiant Biosciences Inc
• Orchard Therapeutics plc
• Mustang Bio Inc
• Rocket Pharmaceuticals Inc
• Enzon Pharmaceuticals Inc
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Pfizer Inc
• Novartis AG
• GlaxoSmithKline plc
• F Hoffmann-La Roche Ltd
• AstraZeneca plc
• Merck & Co Inc
• Eli Lilly and Company
• Amgen Inc
• Bayer AG
• Johnson & Johnson Services Inc
• Teva Pharmaceutical Industries Ltd
• Viatris Inc
• Sandoz International GmbH

結論與建議

Global Adenosine Deaminase Severe Combined Immunodeficiency Market size was valued at USD 284.1 Million in 2024 and is poised to grow from USD 300.63 Million in 2025 to USD 7.96 Million by 2033, growing at a CAGR of 5.82% during the forecast period (2026-2033).

The global market for Adenosine Deaminase deficient Severe Combined Immunodeficiency (ADA-SCID) is centered around innovative therapies focused on replacing or correcting the missing enzyme, crucial for preventing life-threatening infections in vulnerable infants. The rarity of this condition, coupled with the significant treatment costs, has led to government and insurer support for advanced therapies. The evolution of this market has been marked by the emergence of enzyme-replacement therapies and groundbreaking gene-editing technologies, including CRISPR, which facilitate durable immune reconstitution with fewer treatments. As the pipeline expands, automation in gene editing is enhancing production efficiency, lowering costs, and enabling smaller biotech firms to participate. This trend, supported by real-world data showcasing effective outcomes, is drawing investors and expanding patient access globally, ultimately driving market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Adenosine Deaminase Severe Combined Immunodeficiency market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Adenosine Deaminase Severe Combined Immunodeficiency Market Segments Analysis

Global adenosine deaminase severe combined immunodeficiency market is segmented by therapy type, treatment stage, route of administration, end user, distribution channel and region. Based on therapy type, the market is segmented into Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplantation (HSCT) and Gene Therapy. Based on treatment stage, the market is segmented into First-Line Treatment and Subsequent/Salvage Treatment. Based on route of administration, the market is segmented into Intravenous (IV) and Intramuscular (IM). Based on end user, the market is segmented into Hospitals, Specialty Clinics and Transplant Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Adenosine Deaminase Severe Combined Immunodeficiency Market

The market for adenosine deaminase severe combined immunodeficiency is significantly driven by advancements in gene-based therapies, which offer improved safety profiles, more efficient manufacturing processes, and greater regulatory acceptance. These factors help diminish obstacles for both clinicians and patients, thereby boosting confidence among healthcare providers and prompting investments in specialized facilities. This dynamic accelerates patient enrollment in clinical programs, ultimately broadening the market's reach and fostering stable growth across various regions. Additionally, it encourages collaboration among academic institutions, biotechnology companies, and patient advocacy organizations, creating a supportive ecosystem that enhances overall market momentum.

Restraints in the Global Adenosine Deaminase Severe Combined Immunodeficiency Market

The global market for adenosine deaminase severe combined immunodeficiency therapies faces significant challenges primarily due to the complexities involved in gene-based treatments. The manufacturing processes, specialized delivery systems, and the need for extensive clinical monitoring contribute to high costs that complicate reimbursement efforts. Payers frequently demand in-depth cost-effectiveness evaluations, which can result in delayed or limited reimbursement decisions, thereby restricting patient access to care and hindering wider adoption among healthcare professionals. These financial challenges create barriers that reduce the potentially addressed patient population and slow down investment in necessary ancillary services. Additionally, restrictions in funding programs often limit participation in clinical trials, further inhibiting market progress.

Market Trends of the Global Adenosine Deaminase Severe Combined Immunodeficiency Market

The Global Adenosine Deaminase Severe Combined Immunodeficiency market is witnessing a transformative shift driven by innovative gene therapy modalities. Cutting-edge gene editing technologies, including CRISPR-Cas9 and base editing, are revolutionizing treatment approaches for adenosine deaminase deficiency, offering unprecedented precision in rectifying pathogenic mutations while maintaining immune system integrity. This wave of advancement, bolstered by collaborative research initiatives, is yielding promising results in preclinical studies and early-stage trials, highlighting favorable safety profiles. Increased investment from biotech companies is expanding the pipeline of innovative therapeutic candidates, suggesting a significant evolution in long-term disease management for affected infants and their families beyond traditional enzyme replacement therapies.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Adenosine Deaminase Severe Combined Immunodeficiency Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Enzyme Replacement Therapy (ERT)
• Hematopoietic Stem Cell Transplantation (HSCT)
• Gene Therapy

Global Adenosine Deaminase Severe Combined Immunodeficiency Market Size by Treatment Stage & CAGR (2026-2033)

• Market Overview
• First-Line Treatment
• Subsequent/Salvage Treatment

Global Adenosine Deaminase Severe Combined Immunodeficiency Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous (IV)
• Intramuscular (IM)

Global Adenosine Deaminase Severe Combined Immunodeficiency Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Transplant Centers

Global Adenosine Deaminase Severe Combined Immunodeficiency Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Adenosine Deaminase Severe Combined Immunodeficiency Market Size & CAGR (2026-2033)

• North America (Therapy Type, Treatment Stage, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Therapy Type, Treatment Stage, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Treatment Stage, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Treatment Stage, Route of Administration, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Treatment Stage, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Leadiant Biosciences Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orchard Therapeutics plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mustang Bio Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rocket Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enzon Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations